A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients

NCT ID: NCT00849875

Last Updated: 2017-07-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-05-26
• Study Completion Date: 2014-11-17

Brief Summary

The purpose of this clinical trial is to find out how successfully, patients with progressive metastatic cutaneous melanoma, are able to develop an immune response to injections with the immunotherapeutic product GSK1572932A when given in combination with dacarbazine and evaluate the safety of this combination.

Detailed Description

This Protocol Posting has been updated following amendment 3, dated 16 October 2009. The sections impacted are :

• Enrollment, number of subjects
• Outcome measures
• Exclusion criteria

Conditions

Melanoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A

All patients are to receive the same treatment consisting of 24 injections of the immunotherapeutic GSK2132231A combined with a course of 8 cycles of dacarbazine given at the beginning of the treatment

Group Type: EXPERIMENTAL

Immunotherapeutic GSK2132231A

Intervention Type: BIOLOGICAL

Intramuscular administration

Dacarbazine

Intervention Type: DRUG

Intravenous administration Chemotherapy

Interventions

Immunotherapeutic GSK2132231A

Intramuscular administration

Intervention Type: BIOLOGICAL

Dacarbazine

Intravenous administration Chemotherapy

Intervention Type: DRUG

Other Intervention Names

DTIC; Imidazole Carboxamide; DTIC-Dome

Eligibility Criteria

Inclusion Criteria

1. Male or female patient with histologically proven, measurable metastatic cutaneous melanoma

2. Written informed consent has been obtained from the patient before the performance of any protocol-specific procedure.

3. Patient is >= 18 years of age at the time of signature of the Informed Consent.

4. The patient's tumor shows expression of MAGE-A3 antigen, detected by Reverse-Transcription Polymerase Chain Reaction (RT-PCR).

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

6. The patient has normal organ functions.

7. If the patient is female, she must be of non-childbearing potential, or, if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during all the study treatment period and for 2 months after completion of the treatment administration series.

8. In the view of the investigator, the patient can and will comply with the requirements of the protocol.

Exclusion Criteria

1. The patient has at any time received systemic (bio)-chemotherapy.

2. The patient is scheduled to receive any other anticancer treatments than those specified in the protocol, including but not limited to (bio)-chemotherapy, immunomodulating agents and radiotherapy.

3. The patient requires concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents.

4. The patient received any cancer immunotherapeutic containing a MAGE-A3 antigen or any cancer immunotherapeutic for his/her metastatic disease.

5. The patient has received any investigational or non-registered drug or vaccine other than the study medication within the 30 days preceding the first dose of study treatment, or plans to receive such a drug during the study period.

6. The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.

7. History of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.

8. The patient has an autoimmune disease such as, but not limited to, multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.

9. The patient has a family history of congenital or hereditary immunodeficiency.

10. The patient is known to be positive for the Human Immunodeficiency Virus (HIV).

11. The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures.

12. The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.

13. For female patients: the patient is pregnant or lactating.

14. The patient has an uncontrolled bleeding disorder.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Brussels, , Belgium

GSK Investigational Site

Brussels, , Belgium

GSK Investigational Site

Brussels, , Belgium

GSK Investigational Site

Liège, , Belgium

GSK Investigational Site

Roeselare, , Belgium

GSK Investigational Site

Yvoir, , Belgium

GSK Investigational Site

Caen, , France

GSK Investigational Site

Lille, , France

GSK Investigational Site

Marseille, , France

GSK Investigational Site

Nantes, , France

GSK Investigational Site

Paris, , France

GSK Investigational Site

Paris, , France

GSK Investigational Site

Reims, , France

GSK Investigational Site

Villejuif, , France

Countries

Belgium; France

References

Grob JJ, Mortier L, D'Hondt L, Grange F, Baurain JF, Dreno B, Lebbe C, Robert C, Dompmartin A, Neyns B, Gillet M, Louahed J, Jarnjak S, Lehmann FF. Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. ESMO Open. 2017 Nov 14;2(5):e000203. doi: 10.1136/esmoopen-2017-000203. eCollection 2017.

Reference Type: DERIVED

PMID: 29177094 (View on PubMed)

Other Identifiers

111714

Identifier Type: -

Identifier Source: org_study_id